Forecasting Art Coverage in Malawi Using the Multilayer Perceptron Neural Network

Abstract

In this study, the ANN approach was applied to analyze ART coverage in Malawi. The employed annual data covers the period 2000-2018 and the out-of-sample period ranges over the period 2019-2023. The residuals and forecast evaluation criteria (Error, MSE and MAE) of the applied model ANN (9, 12, 1) indicate that the model is stable in forecasting ART coverage in Malawi. The results of the study indicate that ART coverage is likely increase slightly over the period 2019-2023. The government is encouraged to create more demand for ART and HIV testing services, increase HIV testing capacity and strengthen tracking of loss to follow up ART patients amongst other measures

Country : Zimbabwe

1 Dr. Smartson. P. NYONI2 Thabani NYONI

  1. ZICHIRe Project, University of Zimbabwe, Harare, Zimbabwe
  2. Department of Economics, University of Zimbabwe, Harare, Zimbabwe

IRJIET, Volume 5, Issue 3, March 2021 pp. 222-226

doi.org/10.47001/IRJIET/2021.503037

References

  1. Drain PK & Rousseau C (2017). Point-of-care diagnostics: extending the laboratory network. Curr Opin HIV/ AIDS. 2017; 12: 175–181.
  2. IOM (2018). World Migration Report 2018. Available at https://www.iom.int/wmr/world-migration-report-2018
  3. Nyoni & Nyoni T (2019). Forecasting TB notifications at Silobela District Hospital, Zimbabwe.IJARIIE 5(6)2395-4396.
  4. Nyoni & Nyoni T (2019). Forecasting TB notifications at Zengeza clinic, Zimbabwe. Online at https://mpra.ub.uni-muenchen.de/97331/ MPRA Paper No. 97331, posted 02 Dec 2019 10:13 UTC
  5. Pham MD., Agius PA., Romero L., McGlynn P., Anderson D, & Crowe SM(2016). Acceptability and feasibility of point-of-care CD4 testing on HIV continuum of care in low and middle income countries: a systematic review. BMC Health Serv Res.  16: 343. https://doi.org/10.1186/s12913-016-1588-y PMID: 27484023
  6. Roberts T., Cohn J., Bonner K &Hargreaves S (2016). Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges. Clin Infect Dis. 62(8): 1043–8. https://doi. org/10.1093/cid/ciw001 PMID: 26743094
  7. Smartson. P. Nyoni, Thabani Nyoni, Tatenda. A. Chihoho(2020)  PREDICTION OF DAILY NEW COVID-19 CASES IN GHANA USING ARTIFICIAL NEURAL NETWORKS IJARIIE Vol-6 Issue-6             2395-4396
  8. Smartson. P. Nyoni., Thabani Nyoni., Tatenda. A. Chihoho (2020)  PREDICTION OF DAILY NEW COVID-19 CASES IN EGYPT USING ARTIFICIAL NEURAL NETWORKS IJARIIE-  Vol-6 Issue-6         2395-4396
  9. Tanser F., Barnighausen T., Vandormael A., & Dobra A (2015). HIV treatment cascade in migrants and mobile populations. Curr Opin HIV AIDS 10(6):430–8. https://doi.org/10.1097/COH.
  10. UNITAID (2015): HIV/AIDS Diagnostics Technology Landscape. 5thEdition. http://unitaid.eu/ assets/UNITAID_HIV_Nov_2015_Dx_Landscape.pdf
  11. Urassa D P., Matemu S& Sunguya B F (2018). Antiretroviral therapy clinic attendance among children aged 0–14 years in Kahama district, Tanzania: a cross-sectional study. Tanzan J Health Res. 2018;20
  12. Weng SF., Reps J., Kai J., Garibaldi JM &Qureshi N (2017).Can machine learning improve cardiovascular risk prediction using routine clinical data? Plos One 12
  13. WHO (2008). The Maputo Declaration on Strengthening of Laboratory Systems. http://www. who.int/diagnostics laboratory/Maputo-Declaration_2008.pdf
  14. WHO (2015). Consolidated guidelines on HIV testing services. Geneva. http://www.who.int/hiv/pub/guidelines/hiv-testing-services/en/
  15. WHO (2016). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva.
  16. WHO (2018). Access to antiretroviral and direct-acting antiviral medicines, and HIV diagnostics. 2016 update. WHO: Geneva.